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Human African Trypanosomiasis (HAT) also called sleeping sickness is an infectious dis-
ease in humans caused by an extracellular protozoan parasite. The disease, if left
untreated, results in 100%mortality. Currently available drugs are full of severe drawbacks
and fail to escape the fast development of trypanosoma resistance. Due to similarities in
cell metabolism between cancerous tumors and trypanosoma cells, some of the current reg-
istered drugs against HAT have also been tested in cancer chemotherapy. Here we demon-
strate for the first time that the simple ester, ethyl pyruvate, comprises such properties.
Results
The current study covers the efficacy and corresponding target evaluation of ethyl pyruvate
on T. brucei cell lines using a combination of biochemical techniques including cell prolifera-
tion assays, enzyme kinetics, phasecontrast microscopic video imaging and ex vivo toxicity
tests. We have shown that ethyl pyruvate effectively kills trypanosomes most probably by
net ATP depletion through inhibition of pyruvate kinase (Ki = 3.0±0.29 mM). The potential of
ethyl pyruvate as a trypanocidal compound is also strengthened by its fast acting property,
killing cells within three hours post exposure. This has been demonstrated using video
imaging of live cells as well as concentration and time dependency experiments. Most
importantly, ethyl pyruvate produces minimal side effects in human red cells and is known
to easily cross the blood-brain-barrier. This makes it a promising candidate for effective
treatment of the two clinical stages of sleeping sickness. Trypanosome drug-resistance
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tests indicate irreversible cell death and a low incidence of resistance development under
experimental conditions.
Conclusion
Our results present ethyl pyruvate as a safe and fast acting trypanocidal compound and
show that it inhibits the enzyme pyruvate kinase. Competitive inhibition of this enzyme was
found to cause ATP depletion and cell death. Due to its ability to easily cross the blood-
brain-barrier, ethyl pyruvate could be considered as new candidate agent to treat the hemo-
lymphatic as well as neurological stages of sleeping sickness.
Introduction
Human African Trypanosomiasis (HAT) also called sleeping sickness is a re-emergent disease,
but does not attract much attention, probably because its impact is regional.
The two subspecies of T. brucei known to cause HAT are T. brucei gambiense (T. b. gam-
biense) and T. brucei rhodesiense (T. b. rhodesiense). A third subspecies, T. brucei brucei (T. b.
brucei), is only infectious to animals and is commonly used as an experimental model for the
two other parasite species [1,2,3]. The T. b. gambiense brings the chronic form of HAT in West
and Central Africa, representing more than 98% of all reported cases. T. b. rhodesiense results
in the acute form of the disease in East and Southern Africa, representing 2% of all reported
cases. Until now, it has been estimated that the actual number of cases is at least 20,000–30,000
the vast majority of which are not diagnosed or treated [4].
Currently available drugs suffer from contraindications; meanwhile, patient demands for
hospitalization and treatment is high [5,6,7]. Identification of innovative drug targets that are
safe, efficacious, cost effective and easy to administer is therefore a research priority.
A new treatment option, nifurtimox-eflornithine combination therapy (NECT), recently
listed under the essential drugs of WHO to treat neglected tropical diseases, seems promising
except that it still produces side-effects in 68% of patients [8,9].
Some trypanocidal drugs have been previously investigated for their anti-cancer activities
[10]. The probable similarities among trypanosome and cancer cells are their fast proliferation
characteristics and their robust glycolytic pathway [11,12]. However, the glycolytic chain in T.
brucei has a number of peculiarities. Most of its glycolytic enzymes are localized within mem-
brane bound organelles called glycosomes and pyruvate is released out of the cells as a final
product of the glycolysis instead of lactate in mammalian cells. T. brucei bloodstream forms
essentially depend on glycolysis as many enzymes of the tricarboxylic acid cycle and cyto-
chromes are not expressed in the mitochondrion [13]. This shows the physiological essentiality
of pyruvate export in T. brucei. A recent study has also confirmed the role of pyruvate trans-
porter blockage as a promising target in trypanosomes [14]. Recently, the dicarbonyl com-
pound, ethyl pyruvate, has been shown to combat glycolysis-driven tumor cells through
inhibition of the activity of glyoxalases, which are involved in metabolism of methyglyoxal
[15,16].
However, this mechanism may not be the same in T. brucei cells because of the absence of a
functional glyoxalase I enzyme [17]. Besides the speculated mechanisms of action of ethyl
pyruvate at the cellular level e.g. inhibition of the NF-kappaB pathway may not apply for T.
brucei [18].
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Surprisingly, in the present study we observed a strong anti-trypanosomal activity of ethyl
pyruvate. Our current results indicate that this is most probably brought about by inhibition
of an important regulatory enzyme within the glycolytic pathway, namely pyruvate kinase.
Inhibition of this enzyme was found to cause a significant and fast depletion of ATP and conse-
quently death of trypanosome cells. These results indicate that ethyl pyruvate might be a lead
compound which warrants further structural optimization to become a promising candidate
for the treatment of trypanosomiasis.
Results
Effect of ethyl pyruvate on T. brucei cells proliferation and their energy
metabolism
We first analysed the effect of increasing concentrations (1–20 mM) of ethyl pyruvate and its
reduced form, ethyl lactate, on proliferation of the T. brucei cells (strain TC-221). The samples
without ethyl pyruvate were considered as blank controls. The result revealed that ethyl pyru-
vate effectively inhibits cell proliferation with an IC50 of 2.03 ±0.25 mM. The minimum ethyl
pyruvate concentration that gives maximum inhibition was 5 mM (Fig 1A). Interestingly, ethyl
lactate did not inhibit the cells (Fig 1B). This was surprising, because the difference between
the two compounds is just the presence of two additional protons in ethyl lactate.
Next we analysed the effect of ethyl pyruvate at different time points of incubation. The pro-
liferation of trypanosomes was completely inhibited at 5 mM ethyl pyruvate after 3 hrs of incu-
bation indicating that ethyl pyruvate kills trypanosomes within a short time of contact. At
lower concentrations of ethyl pyruvate the inhibitory effect was reduced. No inhibition was
observed at concentrations<1 mM ethyl pyruvate (Fig 1C).
To analyse whether ethyl pyruvate inhibits trypanosomes irreversibly, trypanosomes were
incubated with variable concentrations of ethyl pyruvate for 3 hrs, then the medium was
removed and the cells were finally replenished in fresh medium in the absence of ethyl pyruvate
for 24 hrs (Fig 1D). Cells exposed to low concentration of the ethyl pyruvate ( 2.5 mM) pre-
served their vitality, continued to proliferate and were capable of recovering from the cytotoxic
effect of ethyl pyruvate. However, at a concentration of5 mM the cells were irreversibly dam-
aged and completely lost their cellular integrity.
In vitro drug resistance
The rationale of this test was to analyse whether the trypanosomes become resistant to treat-
ment by ethyl pyruvate. Therefore, T. brucei parasites were cultured in medium containing
sub-lethal concentrations of ethyl pyruvate of 1 mM and 2 mM, respectively, for 30 days
accompanied by changing of the medium every two days. Then, the cells were subjected to
increasing concentrations of ethyl pyruvate (1 to 20 mM) and the proliferation capacity was
determined. The results finally showed that the parasites failed to develop resistance against
ethyl pyruvate during the selected period of exposure at least under in vitro conditions (Fig
2A). In addition to ethyl pyruvate and ethyl lactate, the sodium salt of pyruvate was also tested
for its effect on T. brucei cells proliferation. The result showed no statistically significant inhibi-
tion at least in the range from 0 to 15 mM (Fig 2B).
Comparative anti-proliferative effects of pentamidine and suramin
Currently, the registered first-stage sleeping sickness treatment drugs are pentamidine and sur-
amin. Suramin is an analogue of Trypan Blue that has been used for treatment of sleeping sick-
ness for many years [19]. Pentamidine belongs to the class of aromatic diamidines previously
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designed for prevention and treatment of pneumocystic pneumonia, leishmaniasis and first
stage infection of T. gambiense [20]. It was our intent to compare the anti-trypanosomal activ-
ity of ethyl pyruvate with these standard drugs used in sleeping sickness treatment. As demon-
strated in Fig 3A the proliferation of trypanosomes is inhibited by pentamidine at quite lower
concentrations compared to ethyl pyruvate. Suramin demonstrated anti-proliferative effects in
the range of 100 nM and 1 μM, however no complete inhibition even after 48 hrs of incubation
at the maximum applied concentration of 3855 nM was achieved (Fig 3B). The time-depen-
dency test revealed measurable effects of pentamidine only at 48 hrs of incubation (Fig 3C).
The death rate of pentamdine treated T. brucei indicated that more than 80% of the cells could
Fig 1. Effect of ethyl pyruvate and ethyl lactate on T. brucei cells proliferation. A cell proliferation/viability assay was conducted in 96-well cell culture
plates containing 2x104 cells, medium and ethyl pyruvate in a volume of 200 μl. After 24 hrs of incubation the AlamarBlue cell proliferation reagent (20 μl)
was added and the absorbance was read: (A) Ethyl pyruvate; (B) Ethyl lactate; (C) For the time-dependency test 2x105 cells/ml were cultured in 24-well
plates in the presence of different concentrations of ethyl pyruvate at 0 mM (■), 1 mM (▲), 2.5 mM (x) and 5 mM (□). After certain time intervals aliquots were
removed and the number of vital cells was counted. (D) For cell-recovery test 2x105 cells/ml were cultured in the presence of ethyl pyruvate at 0 mM (■),
1 mM (▲), 2.5 mM (▼), 5 mM (□) for 3 hrs in 24-well plates. Then, the medium was removed and the cells were replenished with fresh medium without the ethyl
pyruvate and further cultured for 24 hrs. At the indicated time points aliquots were removed and vital cells were counted. Cells were cultured at 37°C
containing 5% CO2 in a 100% humidified environment, * p<0.05.
doi:10.1371/journal.pone.0137353.g001
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be killed after 24 hrs of incubation and complete inhibition of cell proliferation was obtained
only at the highest concentration of 128 nM and after 48 hrs. The cell-recovery tests with
pentamidine confirmed its cytostatic effect at 64 nM and full cytotoxicity (non-recovery) at
Fig 2. Drug resistance test for T. brucei using sublethal concentrations of ethyl pyruvate and effect of
pyruvate on cell proliferation. (A) Cells were treated with sub-lethal concentration of ethyl pyruvate, 1 mM
and 2 mM, respectively, for 30 days in separate cell culture flasks. The medium and the trypanocidal
compound were changed every two days. The control cells were left in fresh medium without ethyl pyruvate.
On day 31, 2x104 cells/100μl from each flask were suspended a 96-well plate. Each cell group was treated
with ethyl pyruvate at increasing concentrations ranging from 1 to 20 mM. Absorbance was recorded at 48 hrs
of incubation. (B) The impact of pyruvate (0–20 mM) on cell proliferation was analysed as described in Fig 1.
doi:10.1371/journal.pone.0137353.g002
Fig 3. Anti-proliferative effects of pentamidine and suramin on T. brucei. Cell proliferation/viability was assayed as described in Fig 1 with the exception
of the use of (A) pentamidine and (B) suramin at variable concentrations. (C) Time dependency of anti-proliferative effects of pentamidine at variable
concentrations (12.8 to 128 nM) was performed analogously to the experiments shown in Fig 1. Control samples contained 100 μl of fresh medium instead of
a trypanocidal compound. Pentamidine concentrations used were: 0 nM (■), 12.8 nM (▲), 51.2 nM (▼), 64 nM (♦) and 128 nM (●). (D) Recovery test of T.
brucei cells exposed to pentamidine was done in 24-well in the presence of pentamidine (12.8 nM to 128 nM). Pentamidine concentrations used were: 0 nM
(■), 12.8 nM (▲), 51.2 nM (▼), 64 nM (♦) and 128 nM (●).The results depict the mean of three independent measurements (n = 3), *p<0.05.
doi:10.1371/journal.pone.0137353.g003
Impact of Ethyl Pyruvate on Trypanosomes
PLOSONE | DOI:10.1371/journal.pone.0137353 September 4, 2015 6 / 19
concentrations128 nM at long term incubation (Fig 3D). Compared to pentamidine, ethyl
pyruvate, however, was a very fast acting and irreversible growth inhibitor.
Effect of ethyl pyruvate at cellular ATP level
The sudden loss of viability of trypanosomes at short-time incubation with ethyl pyruvate
prompted us to look at the energy budget of the cells assuming that ATP depletion may be a
possible cause of its extreme cytotoxicity against T. brucei. Our results revealed that the cellular
ATP level was significantly hampered. There was a clear concentration-dependent loss of cellu-
lar ATP in the presence of ethyl pyruvate (Fig 4). The result indirectly demonstrated that ethyl
pyruvate might hamper the glycolytic pathway which is the sole energy-rich phosphate deliver-
ing pathway in trypanosomes.
Effect of ethyl pyruvate on the activity of glycolytic enzymes
The results shown above let us assume that ethyl pyruvate most probably interferes with the
glycolytic pathway in trypanosomes. The enzymes critical for the survival of blood stream form
trypanosomes that might directly affect the ATP production are hexokinase-1 (HK-1), phos-
phofructokinase (PFK) and pyruvate kinase (PK). Therefore, we analyzed the specific activity
of these glycolytic enzymes in trypanosome extracts in the absence and presence of 10 mM
ethyl pyruvate. This concentration was selected because of its maximum effects obtained in all
Fig 4. Effect of ethyl pyruvate at cellular ATP level in T. brucei. Trypanomomes (3x105 cells/well) were
cultured in 24-well plates in the absence (control) or presence of ethyl pyruvate (1 to 20mM) and incubated for
3 hrs at 37°C in 5%CO2. After incubation, cells were centrifuged at 1500 rpm for 10min and supernatant was
removed. The cell sediment was re-suspended smoothly in 500 μl of fresh medium. From this suspension 50 μl
(equivalent to 3x104 cells) was added into a 96-well black opaque-walled plate in duplicates and mixed with
50 μl of test reagent per well. Luminescence was read at 560 nm. The actual ATP level was calculated from the
trend line formula of the standard curve (n = 3), *p<0.05.
doi:10.1371/journal.pone.0137353.g004
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tests so far. As demonstrated in Fig 5A and 5B, ethyl pyruvate was unable to inhibit the activity
of HK-1 and PFK in cell extracts. In contrast to these enzymes the activity of the PK was signif-
icantly inhibited at a concentration of 10 mM ethyl pyruvate (Fig 5C).
In order to exclude a possible influence of cellular metabolites of the extract on PK kinetics
we used purified PK from rabbit muscle for detailed kinetic studies. Thus, we analyzed the sub-
strate-enzyme activity relation in the absence and presence of variable concentrations of ethyl
pyruvate and phosphoenolpyruvate (PEP), respectively. Fig 6 shows the Km (± SD) values for
the control (without ethyl pyruvate), and at different ethyl pyruvate concentrations in depen-
dence of the substrate concentration. From the obtained saturation curves the Ki value was cal-
culated. Data analysis revealed a competitive inhibition of PK activity by ethyl pyruvate with a
Ki = 3.0±0.29 mM.
Fig 5. Effect of ethyl pyruvate on the activity of glycolytic enyzmes of T. brucei. Specific activity of glycolytic enzymes in T. brucei cell extracts in the
absence and presence of 10 mM ethyl pyruvate. (A) hexokinase, (B) phosphofructokinase and (C) pyruvate kinase. All cell extracts were pre-treated with
ethyl pyruvate for 30 min before activity testing. All experiments were performed in triplicates (n = 3), * p<0.05.
doi:10.1371/journal.pone.0137353.g005
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Cytotoxicity of ethyl pyruvate to human red blood cells
To prove whether ethyl pyruvate displayed advantageous selectivity of action against protozoa
cells we performed ex vivo experiments by co-incubation of human red blood cells with the try-
panosomes and ethyl pyruvate for 3 hrs, followed by cell counting and analysis of the red blood
cell hemolysis. As expected, at 5 mM ethyl pyruvate only a few motile cells were observed while
no significant change was seen in the red blood cell count (Fig 7A). The latter finding was sub-
stantiated by a non-significant release of hemoglobin from the red blood cells that remarks the
ethyl pyruvate´s safety at least toward human erythrocytes when compared with the OD of
totally haemolysed blood cells of the same sample used as a positive control (Fig 7B).
Fig 6. Competitive inhibition of pyruvate kinase activity by ethyl pyruvate. Enzyme activity was measured by following the production of ATP from the
substrates phosphoenolpyruvate (PEP) and ADP as described in Materials and Methods. Enzyme activity expressed as nmole ATP/μl/s (ordinate) was
recorded in dependence of increasing substrate concentrations (PEP) in the absence and presence of ethyl pyruvate. Controls were (●) without ethyl
pyruvate (Km = 0.22±0.02 mM); () 5 mM ethyl pyruvate (Km = 0.51±0.03mM); (^) 10 mM ethyl pyruvate (Km = 1±0.08mM) and (Δ) 15 mM ethyl pyruvate
(Km = 1.4±0.08mM). The pure enzyme from rabbit muscle (200 U/mg) was used for the experimental setup to avoid contamination bias in our cell extract. The
Km and Ki values were calculated by SIGMAPLOT (Systat Softwarwe Inc.).
doi:10.1371/journal.pone.0137353.g006
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Phase contrast microscope video imaging of ethyl pyruvate exposed T.
brucei cells
To visualize the effectiveness and fast acting property of ethyl pyruvate we performed video-
recording and phase contrast microscopy of the trypanosome.
The videos showed the features of morphological changes of trypanosoma cells throughout
the 3 hrs incubation time. The cell motility status generally indicates how fast ethyl pyruvate
acts in killing these cells. The fast acting property of ethyl pyruvate can easily be confirmed by
the slow or static motion of the previously active motile cells. The cytotoxic effect of ethyl pyru-
vate started already after 1 hr of exposure and complete inhibition of cell motility finally lead-
ing to cell death was observed after 3 hrs when incubated with 5 mM of the compound. In
contrast to ethyl pyruvate, no visible effect was displayed when using pentamidine at the high-
est toxic concentration of 128 nM within the same time range. The videos show the control
cells without treatment (S1 Video), cells treated with 128 nM pentamidine (S2 Video) and cells
treated with 5 mM ethyl pyruvate (S3 Video).
Discussion
Even though the trypanosome genome was sequenced many years ago, no new breakthroughs
in the treatment of HAT have yet emerged [21], despite the fact that some promising com-
pounds are now in the development pipeline [22,23]. Notably, drugs such as suramin and
nifurtimox with anti-trypanosomal activity have been tested in cancer therapy, too [24,25,26].
A common feature between tumor cells and trypanosomes is the high consumption of glu-
cose. To cover its high energy demand, the parasite uses the host’s glucose for ATP production
[27,28]. Within the glycolytic chain phosphoenolpyruvate is finally converted to pyruvate and
ATP by cytosolic pyruvate kinase. Pyruvate is then released from the cell because of the lack of
a canonical L-lactate dehydrogenase.
Analogously, many tumor cells exhibit a high aerobic glycolysis combined with a restricted
oxidation within the respiratory chain [29]. Instead of pyruvate as in trypanonomes, L-lactate
is produced by tumor cells which provide a growth advantage because of the repression of the
immune system and promotion of cell invasion [30].
Recently, we have shown that compounds containing a dicarbonyl structure such as ethyl
pyruvate, curcumin and different polyphenols are capable to kill tumor cells by inhibition of
glyoxalases [25,31]. These enzymes prevent glycolysis-driven cellular damage by converting
the toxic methyl glyoxal to D-lactate [32].
These findings prompted us to study the effect of ethyl pyruvate on trypanosomes which,
like most tumor cells, have a high glycolytic rate. However, we are aware that T. brucei lacks
glyoxalase I and uses trypanothione instead of glutathione unlike in mammalian cells. Never-
theless, we surprisingly found that ethyl pyruvate effectively inhibited proliferation of the
trypanosomes.
In search of another target within the glycolytic pathway we analysed key enzymes which
are directly involved in the regulation of ATP production in T. brucei, e.g. HK-1, PFK and PK
Fig 7. Cytotoxicity evaluation of ethyl pyruvate on human erythrocytes. (A) 6x105 red blood cells were mixed to 2x105 T. brucei cells in 5 ml fresh
medium in a flask. Cells were first incubated at 37°C in 5% CO2 for 24 hrs. Out of this 1 ml-aliquots were distributed into 24-well plates and incubated with
100 μl of increasing concentrations of ethyl pyruvate (1–15 mM). Controls contained cells without ethyl pyruvate but 100 μl of fresh medium. The cells were
then re-incubated for 3 hrs. Afterwards, the number of trypanosomes and human erythrocytes was counted using a haemocytometer. (B) Effect of ethyl
pyruvate (10 mM) on red blood cell haemolysis was determined by measuring the optical density of the medium containing the T. brucei and red blood cells
co-incubated for 3 hrs. Before measurement, the cells were spun down by centrifugation. Total haemolysis of an equivalent number of cells (labelled as
‘Control’) was achieved by sonication (70% power, 5x5 sec) using an ultrasonicater. Cells without ethyl pyruvate were used as negative controls (labelled as
‘Blank’).
doi:10.1371/journal.pone.0137353.g007
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[33]. While PFK and HK were not inhibited significantly, competitive inhibition of PK
(Ki = 3.0±0.29 mM) by ethyl pyruvate has been ascertained for the first time. PK activity is rela-
tively abundant in the cytosol of T. brucei and is responsible for the net ATP production by the
cell. While most cellular ATP is consumed by hexokinase and phosphofructokinase which are
not under regulatory control, inhibition of PK would lead to a rapid loss of cellular ATP.
Recently, it was found that loss of PK is lethal to glucose-adapted cells [34]. These data corrob-
orate our results that PK is a new target of ethyl pyruvate. Detailed kinetic analysis revealed a
competitive inhibition of PK by ethyl pyruvate. Surprisingly, neither the enzyme nor trypano-
some cells could be inhibited by ethyl lactate. The absence of any anti-proliferative effect of this
compound suggests that the reduced form is either not taken up by the cells or not converted
to ethyl pyruvate because these cells are deprived of lactate dehydrogenase. Admittedly, per-
forming kinetic analysis with mammalian PK and not with purified enzyme from trypano-
somes is obviously a drawback of our study. However, trypanosome PK similar to mammalian
PK responds to fructose 2,6-bisphosphate as an allosteric activator and require Mg2+ ions for
full activity [35]. Furthermore, pphylogenetic and structural analysis clearly showed that the
enzymes of trypanosomatids and yeast belong within the same grouping of species and demon-
strate optimal similarity [36].
We found complete inhibition of trypanosomes at 5 mM ethyl pyruvate within 3 hrs (Fig 1).
This effect was irreversible as no recovery of the cells was observed. Although the concentration
of ethyl pyruvate (5 mM) is slightly above the Ki-value of PK (3.0±0.29 mM) for ethyl pyruvate,
it in turn seemed to be sufficient to initiate a progressive loss of cellular ATP.
Until recently, the development of drug resistance in microbes and protozoa has been a big
challenge in therapeutic medicine. Thus, the lack of drug resistance development we observed
in our in vitro experiments at least over a time laps of 30 days is very encouraging. This could
be due to the attack of more than one target in trypanosomes since it is known that ethyl pyru-
vate also inhibits glyoxalase II in mammalian as well as yeast cells [15]. This enzyme is present
in T. brucei cells but with yet undefined functions [37]. In contrast to the natural evolutionary
pressure in parasites, it is possible that only 30 days of in vitro exposure might be too short to
draw determinative conclusions. However, we also expect that the laboratory adapted T. brucei
cells are capable of proliferating faster and possibly acquiring drug resistance in a shorter
period of exposure.
It has been discussed that monocarboxylates, which are structurally analogous to ethyl pyru-
vate, affects cell proliferation by blocking the pyruvate transporter. This transporter usually
brings the toxic accumulation of the endogenous pyruvate leading to cell death by acidification
[38,39,40]. We addressed this question, by exposing trypanosomes with sufficiently higher con-
centrations of pyruvate. This should stop the efflux of the endogenous pyruvate that might
cause the proposed intracellular acidification. However, the impact of extracellular pyruvate on
vitality of the T. brucei cells was negligible (Fig 2B). This may indirectly indicate the require-
ment of the dicarbonyl structural element in ethyl pyruvate and that pyruvate transporters
blockage might still not be the mode of action of ethyl pyruvate in T. brucei cells [39].
The selective action of ethyl pyruvate was also confirmed by our ex vivo investigation show-
ing that human red blood cells were not struck by the compound. This is quite surprising
because red blood cells are known to rely on oxidation of glucose to lactate and possess a very
active glyoxalase system [41]. In contrast to tumor cells, the lack of damage to red blood cells
by the generated methylglyoxal might be due to the absence of mitochondria since methyl-
glyoxal was shown to target mitochondria for induction of cell death and also because of their
high level of glutathione [42].
Unlike in T. brucei the red blood cells are known to release lactate and the T. brucei pyruvate
transporter permeases are not related to MCTs from mammals [43]. These might also be
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optional reasons why ethyl pyruvate is safe for red blood cells but not to T. brucei. It should
also be considered, that red blood cells might contain a high amount of unspecific esterases
which could degrade ethyl pyruvate easily.
Ethyl pyruvate is a comparatively safe and fast acting agent against T. brucei. However, a rel-
atively high concentration is required to observe optimal inhibition. This might be considered
as a constraint when compared with the currently registered drugs acting in nanomolar or
micromolar concentrations (Figs 1 and 3). Therefore, for in vivo application ethyl pyruvate has
to be administered in a concentrated solution by infusion in order to get an effective level of at
least 5 millimolar in animals or humans. This route of application was already applied in a
phase II clinical study by using 450 mg/kg/day given in five divided doses without side effects
[44]. Another possibility of minimizing the required high dose of ethyl pyruvate is to chemi-
cally modify the chain length of the alcohol of the ester in order to increase permeability and
inhibitory activity. A similar approach was recently demonstrated for optimizing inhibitors for
trypanosome PFK and Leishmania PK [45].
Conclusion
Our in vitro experimental study presents ethyl pyruvate as a fast acting, effective and safe trypa-
nocidal compound. Pyruvate kinase has been identified as the new target of ethyl pyruvate.
Inhibition of this enzyme was found to cause ATP depletion and sudden cell death. However,
further comprehensive studies are needed with respect to Ki reduction and toxicity evaluation
as well as metabolism in infected animal models. Then, its predefined property to easily cross




Heparinized human blood was obtained from male healthy volunteers in the age of 30 to
40 years. All participants provided their written informed consent to participate in this study.
The local ethics committee of the Faculty of Medicine of the University of Leipzig, Germany,
approved this study in accordance to the ICH-GCP guidelines (reference number: 057–2010–
08032010).
In vitro cultures of Trypanosoma brucei cells
Laboratory adapted T. b. brucei cells (strain TC-221) were obtained from Prof. A. Stich, Würz-
burg, Germany [47]. The cells were cultured in complete Baltz medium which was composed
of 82% Baltz basic solution, 0.8% ß-mercaptoethanol, 0.8% penicillin/streptomycin (10,000 U/
ml), and 16.4% heat inactivated fetal calf serum (FCS). Cells were cultured using 50 ml sterile
cell culture flasks (Greiner Bio-One, Frickenhausen, Germany) at 37°C and 5% CO2 in 100%
humidified environment. The medium was changed every 2–3 days.
Cell proliferation/viability assay
The AlamarBlue cell proliferation assay (Thermo Fisher Scientific, USA) has been used to mea-
sure the metabolically active cells. The principle behind this assay relates to the fact that meta-
bolically active cells create a reducing environment that promotes the conversion of resazurin
(non-fluorescent) to resorufin (highly fluorescent). The absorbance was measured using an
ELISA reader/96-well multiscanner (Tecan, Crailsheim, Germany) at ex550/em630 nm.
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Concentration-response test
The concentration-response assay was performed in 96-well cell culture plates to which 100 μl
of a cell suspension (2x104 cells), 100 μl of the trypanocidal compounds at increasing concen-
trations and 20 μl of AlamarBlue was added. Control wells contained 200 μl of equal number of
cells in fresh medium without trypanocidal compounds. The change in absorbance was
recorded after 24 hrs of incubation. The drugs or compounds used in different experimental
settings were ethyl pyruvate and ethyl lactate, pentamidine-isothionate, suramin and pyruvate
(Sigma-Aldrich, Munich, Germany).
Time-dependency test
The time-dependency test was done in 24-well plates containing 1 ml of cell suspension (2x105
cells/well) and 100 μl of ethyl pyruvate at variable concentrations (1 to 20 mM), or an equal
volume of fresh medium (control). Cells were incubated for 24 hrs at 37°C in a humidified
environment containing 5% CO2. For cell counting, a Neubauer haemocytometer (Marienfeld,
Lauda-Königshofen, Germany) was used. The number of moving cells was recorded after 1 hr,
3 hrs, 6 hrs and 24 hrs of incubation, respectively. Tests were done in triplicates and the mean
and standard deviation were calculated.
Cell-recovery test
The cell-recovery test was done using 1 ml of cells (2x105 cells/ml) seeded into a 24-well plate
to which was added 100 μl of ethyl pyruvate (1 to 20 mM) or pentamidine (12.8 nM to 128
nM). A volume of 100 μl of fresh medium without trypanocidal compounds served as a control.
Cells were exposed to ethyl pyruvate and pentamidine for 3 hrs and 48 hrs, respectively, ali-
quots were removed and centrifuged (1500 rpm, 10 min, 5°C). The supernatant was carefully
removed and the precipitated cells were re-suspended with 1 ml fresh medium without trypa-
nocidal compounds and cultured for another 48 hrs. Vital cells were counted at the beginning
of the re-suspension and continued at 1 hr, 3 hrs, 6 hrs, 24 hrs and 48 hrs afterwards. The tests
were done in triplicate.
In vitro drug-resistance test
Primarily, cells were treated with sub-lethal concentrations of ethyl pyruvate (1 and 2 mM) for
30 days in separate cell culture flasks. The medium and the trypanocidal compounds were
changed every two days. The control cells were left in fresh medium without ethyl pyruvate.
On day 31, 100 μl of 2x104 cells per well were seeded in a 96-well plate. Each cell group was
treated with ethyl pyruvate at increasing concentrations ranging from 1 to 20 mM. Controls
were incubated in fresh medium without ethyl pyruvate. To each well 20 μl of the AlamarBlue
reagent and absorbance was recorded after 48 hrs of incubation.
Cell extracts preparation and protein concentration determination
Cells were harvested and the pellets were first re-suspended at 1:4 ratio in a lysis buffer contain-
ing 25 mM Tris, 2 mM PMSF, 10% Glycerol, 1% Tritonx100, 2 mM EDTA and freshly added
0.3% protease inhibitor cocktail at pH 8.0. The suspension was repeatedly vortexed every 1–2
min within 15 min duration. The cell sediment was always kept on ice. Then the mixture was
centrifuged for 15 min at 13000 x g and 5°C. The supernatant was carefully pipetted into a new
Eppendorf tube and the sediment was discarded. The protein content of samples was deter-
mined according to Bradford [48].
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Determination of the ATP content
Cellular ATP content was determined by means of the CellTiter-Glo luminescent cell viability
assay according to the manufacturer’s instructions (Promega, Madison, USA). Briefly, cells
were cultured in 24-well plates (4x104 cells/well) in the absence or presence of ethyl pyruvate
(1 to 20 mM) and incubated at 37°C and 5% CO2 for 3 hrs. Cells were then mixed with test
reagents and luminescence was read. A standard curve was prepared from ATP (10 nM to
1 μM) in medium to determine the actual ATP level in cells.
Enzyme activity assays
Hexokinase. Hexokinase (HK) (EC 2.7.1.1) activity was measured following up the reduc-
tion of NAD+ through a coupled reaction with glucose-6-phosphate dehydrogenase. The
increase in absorbance was determined spectrophotometrically at 340 nm wavelength accord-
ing to [49]. Briefly, 100 μl of the cell extract was added to 3 ml of 50 mM Tris-buffer containing
13.3 mMMgCl2, 0.67 M glucose, 16.5 mM ATP, 6.8 mMNAD, pH 8.0, and glucose-6-phos-
phate dehydrogenase. The measurements were done in the absence and presence of 10 mM
ethyl pyruvate, respectively.
Phosphofruktokinase. The activity of phosphofructokinase (PFK) (EC 2.7.1.11) in T. bru-
cei was measured at 340 nm in a coupled assay with aldolase (EC 4.1.2.13), glycerol-3-phos-
phate dehydrogenase (EC 1.1.1.8) and triosephosphate isomerase (EC 5.3.1.1) according to
[50]. Activity of phosphofructokinase was measured using 100 μl of T. brucei cell extract.
Pyruvate kinase. To determine kinetics in pyruvate kinase (PK) (EC 2.7.1.40) activity we
first applied the indirect coupled assay using lactate dehydrogenase (LDH) as helper enzyme
[49,50]. However, ethyl pyruvate was found to act itself as a substrate of LDH resulting in a
concentration-dependent concomitant increase in oxidation of NADH to NAD+. Hence the
activity of PK was evaluated by measuring the ATP production using the CellTiter-Glo Lumi-
nescent assay following the manufacturer’s instructions (Promega, Madison, USA). To deter-
mine the inhibition of PK activity in the cell extracts the reaction was initiated by adding 10 μl
of the crude cell extract (1.17 mg/ml protein) to 2 ml of a reaction mixture composed of 200
mM Tris/HCl buffer, 15 mMMgCl2, 2 mM ADP, 3 mM phosphoenolpyruvate and 10 mM
ethyl pyruvate (pH 7.0). The PK activity was read against a standard curve of ATP and
expressed as (nM ATP/μl/s).
The PK kinetics assay was performed by measuring the enzyme activity at increasing con-
centrations of phosphoenolpyruvate (0.1 to 3 mM) in the absence and presence of ethyl pyru-
vate (5, 10 and 15 mM). Purified PK-1 from rabbit muscle (stock of 200 U/mg) was used for
the test. The activity measurements were performed for 10 min at 20°C. The ATP luminescence
measurement was done in a 96-well white opaque plate (Greiner, Frickenhausen, Germany) at
250 milliseconds ATP luminescence integration time using the SoftMax Pro 5.3 software.
Finally, the Vmax, Km and Ki values were calculated to characterize the inhibitory effect of
ethyl pyruvate at the enzyme. The observed data in the presence and absence of ethyl pyruvate
were fit simultaneously for a competitive enzyme inhibition model shown by the equation
below. Nonlinear regression fitting was accomplished with use of SIGMAPLOT (Systat Soft-
ware Inc.) applying a weighting function of 1/Y2. PK activity was expressed as (nM ATP/μl/s).
V ¼ VMAX 
½PEP
ð½PEP þ KM  ð1þ ½EP=KIÞÞ
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Effect of ethyl pyruvate on human red blood cells
Heparinized human blood (5 ml) was centrifuged at 2000 rpm for 15 min and supernatant was
removed. The cells were washed three times with 20 mM sodium phosphate, 150 mM sodium
chloride (PBS), pH 7.4. Human red blood cells (5x105) were mixed to 2x105 T. brucei cells in
5 ml fresh medium in a 25 cm2 culture flask. Cells were incubated at 37°C and 5% CO2 for
24 hrs. Aliquots (1 ml) were taken and distributed into 24-well plates and incubated with
100 μl medium containing increasing concentration of ethyl pyruvate (1 to 15 mM). Controls
contained cells without ethyl pyruvate but 100 μl of fresh medium. The cells were then incu-
bated for 3 hrs. Trypanosome cells and blood cells were counted and the release of haemoglo-
bin in the supernatant after cell centrifugation was measured photometrically at 540 nm. As a
positive control a cell suspension of red blood cells was haemolysed using ultra-sonication to
obtain complete hemolysis of a similar blood specimen not containing ethyl pyruvate.
Phase contrast microscopy and video recording
Culture flasks containing 5 ml of cells (107 cells/ml) were exposed to a final concentration of
5 mM ethyl pyruvate and 128 nM pentamidine. A control flask contained equal number of
cells in fresh medium without trypanocidal compounds. All the cells were incubated for 3 hrs.
For video recording, 5 ml cell suspension (107 cells/ml) was poured into a Nunclon culture
dish (Sigma-Aldrich, Taufkirchen, Germany) with a bottom partially replaced by a glass-slide
to increase imaging quality. The dish was closed with a custom made lid equipped with a CO2
adapter to allow for 5% CO2 supply in air. Cells were observed for three hours on an inverted
phase contrast microscope (DMIRB, Leica) endowed with a 20x Objective (0.4 NA) and a 1x
C-mount. The microscope was enclosed by a self-made thermo-box kept at 37°C to provide
usual cell culture conditions. Videos were recorded every hour for untreated and pentamidine
treated cells. For those cells treated with 5 mM ethyl pyruvate video recording was done every
30 min. The recordings were taken using a Phytec FireWire-CAM-111H with a frame rate of
15 fps. Each video sequence lasts 2 min.
Statistics
All analyses were done using GraphPad Prism 5.0 (GraphPad Software Inc. San Diego, USA).
If not stated otherwise, all statistical tests were made by Mann-Whitney test. P<0.05 had been
considered as significantly different.
Supporting Information
S1 Video. Phase contrast microscope video of live actively moving T. brucei cells. A control
flask contained (107 cells/ml) in 5 ml fresh medium without drugs and assigned as a negative
control. The cells were incubated for 3 hrs and videos were recorded every hour (For details
regarding the method please see the Materials and Methods section). A free downloadable ver-
sion of Freemake Video Converter.exe software was used to sequentially put the video files
together in one video file (Link: http://youtu.be/KIK_zZnJrCM) (login ID: netsanetworku;
password: netsanet32000).
(DOCX)
S2 Video. Phase contrast microscope video of pentamidine treated T. brucei cells. A test
flask contained (107 cells/ml) in 5 ml fresh medium treated with 128 nM pentamidine and
treated as shown in S1 Video. (Link: http://youtu.be/xj5kKmWpz6o) (login ID: netsanetworku;
password: netsanet32000).
(DOCX)
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S3 Video. Phase contrast microscope video of ethyl pyruvate treated T. brucei cells. A test
flask contained (107 cells/ml) in 5 ml fresh medium treated with 5 mM ethyl pyruvate and
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